Title |
Prospects for combined use of oncolytic viruses and CAR T-cells
|
---|---|
Published in |
Journal for Immunotherapy of Cancer, November 2017
|
DOI | 10.1186/s40425-017-0294-6 |
Pubmed ID | |
Authors |
Adam Ajina, John Maher |
Abstract |
With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following the favourable results of several clinical trials, adoptive cell transfer using chimeric antigen receptor (CAR)-redirected T-cells is anticipated to enter routine clinical practice for the management of chemotherapy-refractory B-cell malignancies. However, CAR T-cell therapy for patients with advanced solid tumours has proved far less successful. This Review draws upon recent advances in the design of novel oncolytic viruses and CAR T-cells and provides a comprehensive overview of the synergistic potential of combination oncolytic virotherapy with CAR T-cell adoptive cell transfer for the management of solid tumours, drawing particular attention to the methods by which recombinant oncolytic viruses may augment CAR T-cell trafficking into the tumour microenvironment, mitigate or reverse local immunosuppression and enhance CAR T-cell effector function and persistence. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 10 | 29% |
Denmark | 2 | 6% |
Canada | 2 | 6% |
Russia | 1 | 3% |
Venezuela, Bolivarian Republic of | 1 | 3% |
France | 1 | 3% |
United Kingdom | 1 | 3% |
Singapore | 1 | 3% |
Spain | 1 | 3% |
Other | 2 | 6% |
Unknown | 13 | 37% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 26 | 74% |
Scientists | 5 | 14% |
Practitioners (doctors, other healthcare professionals) | 3 | 9% |
Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 163 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 30 | 18% |
Student > Bachelor | 22 | 13% |
Researcher | 17 | 10% |
Student > Master | 13 | 8% |
Student > Doctoral Student | 7 | 4% |
Other | 11 | 7% |
Unknown | 63 | 39% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 27 | 17% |
Medicine and Dentistry | 19 | 12% |
Agricultural and Biological Sciences | 16 | 10% |
Immunology and Microbiology | 13 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 9 | 6% |
Other | 10 | 6% |
Unknown | 69 | 42% |